Matchpoint Therapeutics is preparing to take its oral T cell modulator through proof-of-concept clinical testing in ...

Anthropic's Claude Science performed impressively in a protein design exercise, designing binders against 14 out of 15 targets and improving, in many cases, on the results of design competitions ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock was ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC). Top-line results from the ...

Hydroxychloroquine, the anti-malaria drug controversially used to fight COVID-19, was trending again after a string of retweets from president Donald Trump in favour of the medicine. Trump has ...

Shares in Abivax were tracking up this morning as a media report in France suggested a takeover by Eli Lilly – worth €15 billion ($17.5 billion) – could be on the cards. French newspaper La Lettre ...

Global chipmaker giant NVIDIA kicked off JPM Week with several partnership announcements, most notably a billion dollar partnership with Indianapolis-based Eli Lilly. "Biology is on the verge of its ...

Isomorphic Labs' chief executive, Sir Demis Hassabis, delivering his Nobel Prize lecture in 2024. Alphabet-backed start-up Isomorphic Labs has added to the lustre attached to its AI-powered drug ...

Zealand Pharma's CEO, Adam Steensberg. Shares in Zealand Pharma lost around a third of their value today, after it reported phase 2 data with Roche-partnered weight-loss therapy petrelintide. The sell ...

It has been announced that global management consulting and technology firm ZS Associates has reached a definitive agreement to acquire Trials.ai, an intelligent study design company that uses ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class therapies ...

Office of Management and Budget (OMB) Director Russell Vought. A move by the Trump administration to block new NIH research funding for external research teams, as well as some renewals, appears to ...